ARCHIVES

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Centers Of Excellence In Interventions Aimed at molecular Targets; Approved On 19-6 Vote

July 2, 1999

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

Advocacy: NCCS, ASCO Petition FDA To Set Standards For Expanded Access Programs.

April 14, 2006

Block, Committee Agree; No New PDQ For General Public

January 11, 1985

Cech To Step Down At HHMI In 2009.

April 18, 2008

Also NCI requests $6.2 billion in FY2005 Bypass Budget.

January 2, 2004